ACAD
Price
$14.74
Change
-$0.00 (-0.00%)
Updated
Oct 28 closing price
8 days until earnings call
FOLD
Price
$11.52
Change
-$0.00 (-0.00%)
Updated
Oct 28 closing price
6 days until earnings call
Ad is loading...

ACAD vs FOLD

Header iconACAD vs FOLD Comparison
Open Charts ACAD vs FOLDBanner chart's image
ACADIA Pharmaceuticals
Price$14.74
Change-$0.00 (-0.00%)
Volume$819.65K
CapitalizationN/A
Amicus Therapeutics
Price$11.52
Change-$0.00 (-0.00%)
Volume$2.1M
CapitalizationN/A
View a ticker or compare two or three
ACAD vs FOLD Comparison Chart
Loading...
ACAD
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
FOLD
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
VS
ACAD vs. FOLD commentary
Oct 30, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACAD is a StrongBuy and FOLD is a StrongBuy.

COMPARISON
Comparison
Oct 30, 2024
Stock price -- (ACAD: $14.74 vs. FOLD: $11.52)
Brand notoriety: ACAD and FOLD are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ACAD: 65% vs. FOLD: 78%
Market capitalization -- ACAD: $2.6B vs. FOLD: $3.18B
ACAD [@Biotechnology] is valued at $2.6B. FOLD’s [@Biotechnology] market capitalization is $3.18B. The market cap for tickers in the [@Biotechnology] industry ranges from $531.34B to $0. The average market capitalization across the [@Biotechnology] industry is $2.92B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ACAD’s FA Score shows that 0 FA rating(s) are green whileFOLD’s FA Score has 0 green FA rating(s).

  • ACAD’s FA Score: 0 green, 5 red.
  • FOLD’s FA Score: 0 green, 5 red.
According to our system of comparison, FOLD is a better buy in the long-term than ACAD.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ACAD’s TA Score shows that 5 TA indicator(s) are bullish while FOLD’s TA Score has 6 bullish TA indicator(s).

  • ACAD’s TA Score: 5 bullish, 3 bearish.
  • FOLD’s TA Score: 6 bullish, 5 bearish.
According to our system of comparison, ACAD is a better buy in the short-term than FOLD.

Price Growth

ACAD (@Biotechnology) experienced а -0.14% price change this week, while FOLD (@Biotechnology) price change was -4.08% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.91%. For the same industry, the average monthly price growth was +2.47%, and the average quarterly price growth was -6.27%.

Reported Earning Dates

ACAD is expected to report earnings on Mar 03, 2025.

FOLD is expected to report earnings on Feb 26, 2025.

Industries' Descriptions

@Biotechnology (+0.91% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
FOLD($3.18B) has a higher market cap than ACAD($2.6B). FOLD YTD gains are higher at: -18.816 vs. ACAD (-52.922). ACAD has higher annual earnings (EBITDA): 34.3M vs. FOLD (-40.33M). ACAD has more cash in the bank: 501M vs. FOLD (260M). ACAD has less debt than FOLD: ACAD (57.7M) vs FOLD (444M). ACAD has higher revenues than FOLD: ACAD (891M) vs FOLD (456M).
ACADFOLDACAD / FOLD
Capitalization2.6B3.18B82%
EBITDA34.3M-40.33M-85%
Gain YTD-52.922-18.816281%
P/E Ratio81.00N/A-
Revenue891M456M195%
Total Cash501M260M193%
Total Debt57.7M444M13%
FUNDAMENTALS RATINGS
ACAD vs FOLD: Fundamental Ratings
ACAD
FOLD
OUTLOOK RATING
1..100
6858
VALUATION
overvalued / fair valued / undervalued
1..100
81
Overvalued
81
Overvalued
PROFIT vs RISK RATING
1..100
10076
SMR RATING
1..100
8098
PRICE GROWTH RATING
1..100
8346
P/E GROWTH RATING
1..100
68100
SEASONALITY SCORE
1..100
8595

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ACAD's Valuation (81) in the Biotechnology industry is in the same range as FOLD (81). This means that ACAD’s stock grew similarly to FOLD’s over the last 12 months.

FOLD's Profit vs Risk Rating (76) in the Biotechnology industry is in the same range as ACAD (100). This means that FOLD’s stock grew similarly to ACAD’s over the last 12 months.

ACAD's SMR Rating (80) in the Biotechnology industry is in the same range as FOLD (98). This means that ACAD’s stock grew similarly to FOLD’s over the last 12 months.

FOLD's Price Growth Rating (46) in the Biotechnology industry is somewhat better than the same rating for ACAD (83). This means that FOLD’s stock grew somewhat faster than ACAD’s over the last 12 months.

ACAD's P/E Growth Rating (68) in the Biotechnology industry is in the same range as FOLD (100). This means that ACAD’s stock grew similarly to FOLD’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ACADFOLD
RSI
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
75%
Bearish Trend 2 days ago
86%
Momentum
ODDS (%)
Bearish Trend 2 days ago
68%
Bullish Trend 2 days ago
78%
MACD
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 2 days ago
71%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
74%
Bearish Trend 2 days ago
79%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
78%
Bullish Trend 2 days ago
74%
Advances
ODDS (%)
Bullish Trend 12 days ago
74%
Bullish Trend 13 days ago
74%
Declines
ODDS (%)
Bearish Trend 7 days ago
73%
Bearish Trend 2 days ago
74%
BollingerBands
ODDS (%)
Bullish Trend 5 days ago
71%
Bearish Trend 2 days ago
73%
Aroon
ODDS (%)
Bearish Trend 2 days ago
78%
Bearish Trend 2 days ago
80%
View a ticker or compare two or three
Ad is loading...
ACAD
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
FOLD
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GME22.732.16
+10.50%
GameStop Corp
BTC.X69907.7600001978.460900
+2.91%
Bitcoin cryptocurrency
AAPL233.401.99
+0.86%
Apple
SPY580.831.79
+0.31%
SPDR® S&P 500® ETF Trust
TSLA262.51-6.68
-2.48%
Tesla

ACAD and

Correlation & Price change

A.I.dvisor indicates that over the last year, ACAD has been loosely correlated with VRTX. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if ACAD jumps, then VRTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ACAD
1D Price
Change %
ACAD100%
+2.79%
VRTX - ACAD
47%
Loosely correlated
-0.28%
DNLI - ACAD
44%
Loosely correlated
+6.27%
FOLD - ACAD
44%
Loosely correlated
-1.45%
CCCC - ACAD
43%
Loosely correlated
+1.87%
ADCT - ACAD
43%
Loosely correlated
+3.73%
More